Sleep Medicine News

The FDA approved an obstructive sleep apnea neurostimulation therapy for patients aged 13 years and older with Down syndrome, according to a manufacturer-issued press release.

Excessive daytime sleepiness is a common symptom of several sleep disorders, including obstructive sleep apnea, which is estimated to affect 10% to 30% of adults in the U.S and often goes underdiagnosed, according to the Sleep Foundation.

Patients with obstructive sleep apnea showed impaired emotional memory after one night of sleep, according to study results published in Annals of the American Thoracic Society.

A recent study by U.S. News & World Report’s 360 Reviews has named Austin, Texas, the best city in the United States for sleep, while Philadelphia was ranked the worst.

On Saturday night, most of us in the U.S. will lose an hour of sleep as we switch to daylight saving time.

Adults with obstructive sleep apnea faced elevated risks for developing COVID-19 and experiencing COVID-19-related complications, according to study results published in Thorax.

The FDA has granted 510(k) clearance to an at-home test device that can diagnose obstructive sleep apnea and other sleep-related breathing disorders, according to a press release.

White individuals who frequently used sleep medication had a greater risk for dementia compared with those who rarely or never used them, though the same association was not found in Black individuals, a new study found.

Aculys Pharma, Inc. announced the initiation of a phase 3 trial of pitolisant, a histamine H3 receptor antagonist/inverse agonist in those with excessive daytime sleepiness that is associated with obstructive sleep apnea syndrome.

Sleep quality in patients with type 1 diabetes may be improved with disease management as well as interventions supporting resilience and reducing negative emotions, researchers reported in BMC Psychiatry.